Navigation Links
FDA Approves Phase I Clinical Trial of Topaz Pharmaceuticals' New Head Lice Treatment

Topaz Pharmaceuticals LLC, a pharmaceutical company dedicated to the health and well being of children, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug application; allowing Topaz to begin clinical trials of the company's topical solution for the treatment of head lice.

The Topaz product is designed to give healthcare professionals a new choice for the treatment of head lice infestations - it will provide a naturally derived treatment that is lethal to lice and nits, yet safe to children and adults. Between 6 and 12 million children are affected by head lice in the United States each year. In many cases, the children with head lice are dismissed from school and not allowed to return until they are declared "lice free" -- impacting parents and children alike.

"This IND approval and the entry of our first subjects into clinical trials bring us closer to a significant milestone in the treatment of head lice," said Nick Spring, Topaz Pharmaceuticals president and chief executive officer.

"Current treatments on the market are either becoming less effective because of lice resistance or contain potentially hazardous substances. We remain confident and optimistic that the Topaz solution will be proven safe and effective in subsequent trials, and will eventually help alleviate the frustration, inconvenience and social stigma associated with head lice."

Topaz Pharmaceuticals LLC is a start-up company, which initially benefited from support provided by the Ben Franklin Technology Partners of Southeast Pennsylvania, who develops and markets pediatric medicines.

The company expects to develop additional indications covering other parasitic insects affecting human health. Topaz Pharmaceuticals is developing a completely novel and kid friendly formulation of a naturally derived, quick acting ingredient which is lethal to head and body lice.


'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... , ... The American public tends to feel uncomfortable about drinking recycled waste ... or well water. The recent experience with lead contaminated water in Flint, Michigan, according ... toward increasing public acceptance of recycled waste water as drinking water. , The ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and ... 2nd Annual No Cost Dental Day to individuals in need. The event is scheduled ... this No Cost Dental Day is to provide dental care to community members in ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a web ... zone to the next using Colorize's dynamic moving camera. Colorize is perfect for personal ... a 3D slideshow environment with 1 to 5 focus points per scene, stage floor ...
(Date:2/5/2016)... ... , ... California Mobile Kitchens , a company that ... mobile kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. ... anywhere in the U.S. Many of their units can be seen at sporting ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology: